Anotherstudy from 2006 investigated the dual kinase inhibitor activity of Lapatinib inHER-2-overexpressing breast cancer cells as well as responses of a panel of 31characterized human breast cancer cell lines to treatment by Trastuzumab,including the use of Trastuzumab-conditioned HER-2(+ve) cell lines [4]. Here, ERBB2 is linked to breast carcinoma.